Inhibrx Biosciences, Inc. (INBX)
(Delayed Data from NSDQ)
$13.02 USD
-0.59 (-4.34%)
Updated Jul 9, 2024 04:00 PM ET
After-Market: $13.09 +0.07 (0.54%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
INBX 13.02 -0.59(-4.34%)
Will INBX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for INBX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for INBX
Inhibrx, Inc. (INBX) Reports Q4 Loss, Tops Revenue Estimates
BioMarin Pharmaceutical (BMRN) Beats Q4 Earnings and Revenue Estimates
INBX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Pharma Stock Roundup: JNJ Reports Q4 Earnings, SNY Inks M&A Deal With INBX
Biotech Stock Roundup: GILD Down on Study Results, INBX Gains on Sanofi Deal & More
Inhibrx, Inc. (INBX) Soars 8.9%: Is Further Upside Left in the Stock?
Other News for INBX
Inhibrx Biosciences Shares Latest Corporate Presentation Update
Inhibrx Biosciences files to sell 2.45M shares of common stock for holders
Inhibrx files to sell 2.45M shares of common stock for holders
Inhibrx: Continued Advancement Even After INBRX-101 Sale To Sanofi
Top 4 Health Care Stocks That Are Preparing To Pump This Month